Skip to main content
Log in

Pharmacokinetics and hypotensive effect in healthy volunteers of pinacidil, a new potent vasodilator

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

Preliminary investigation in 3 healthy volunteers suggested that intravenous pinacidil in a dose of 0.2 mg/kg had a potent but well-tolerated hypotensive action in the supine position. Facial flushing, uncomfortable chest sensation and distressing postural hypotension occurred at serum concentrations above 300 ng/ml. Pinacidil, 0.2 mg/kg, was given intravenously over 4 min to 15 healthy volunteers in the supine position. Maximum fall in mean arterial pressure (MAP) was 15.7±6.0 mmHg. Maximum rise in heart rate was 23.8±6.6 beats/min. Pinacidil serum distribution half-life (\({\text{T}}_{{\raise0.7ex\hbox{${\text{1}}$} \!\mathord{\left/ {\vphantom {{\text{1}} {{\text{2}}\alpha }}}\right.\kern-\nulldelimiterspace}\!\lower0.7ex\hbox{${{\text{2}}\alpha }$}}}\)) was 13.4±8.5 min and elimination half-life (\({\text{T}}_{{\raise0.7ex\hbox{${\text{1}}$} \!\mathord{\left/ {\vphantom {{\text{1}} {{\text{2}}\beta }}}\right.\kern-\nulldelimiterspace}\!\lower0.7ex\hbox{${{\text{2}}\beta }$}}}\)) was 2.13±0.49 h. The apparent volume of distribution (Vdβ) was 90.3±13.21 and total body clearance was 31.1±9.61/h. Pinacidil was approximately 40% bound to plasma protein over the concentration range 40–400 ng/ml. Urinary excretion of unchanged pinacidil accounted for 5.7 ± 1.3% of the administered dose over 24 hours and urinary excretion of the major metabolite, pinacidil pyridine-N-oxide, was 31.6±9.2% of the administered dose. It was concluded that intravenous pinacidil is a potent vasodilator hypotensive compound, with a duration of action between 1.5 and 2 h.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Petersen HJ, Nielsen CK, Arrigoni-Martelli E (1978) Synthesis and hypotensive activity of N-alkyl-N″-cyano-N′-pyridylguanidines. J Med Chem 21: 773–781

    Google Scholar 

  2. Arrigoni-Martelli E, Nielsen CK, Olsen UB, Petersen HJ (1980) N″-cyano-N-4-pyridyl-N′-1,2,2,-trimethylpropylguanidine, monohydrate (P1134): a new potent vasodilator. Experientia 36: 445–447

    Google Scholar 

  3. Thoolen MJMC, van Meel JCA, Wilffert B, Timmermans PBMWM, van Zwieten PA (1983) Haemodynamic characterization of pinacidil in rats. Comparison to hydralazine. Pharmacology 27: 245–254

    Google Scholar 

  4. Nielsen CK, Arrigoni-Martelli E (1981) Effect of a new vasodilator, pinacidil (P1134), on potassium, noradrenaline and serotonin induced concentrations in rabbit vascular tissues. Acta Pharmacol Toxicol 49: 427–431

    Google Scholar 

  5. Mikkelsen E, Pedersen OL (1982) Comparison of the effects of a new vasodilator, pinacidil, and nifedipine on isolated blood vessels. Acta Pharmacol Toxicol 51: 407–412

    Google Scholar 

  6. Carlsen JE, Kardel T, Tage H, Mogens T, Trap-Jensen J (1981) Immediate central and peripheral haemodynamic effects of a new vasodilating agent pinacidil (P1134) in hypertensive man. Clin Physiol 1: 357–384

    Google Scholar 

  7. Muiesan G, Fariello R, Muiesan ML (1983) Effects of pinacidil on blood pressure, plasma catecholamines and plasma renin activity in essential hypertensive patients. Clin Pharmacol Ther 33 [2]: p 229 (abstract)

    Google Scholar 

  8. Eilertsen E, Magnussen MP, Petersen HJ, Rastrup-Andersen N, Sorensen H, Arrigoni-Martelli E (1982) Metabolism of the new antihypertensive agent pinacidil in rat, dog and man. Xenobiotica 12 [3]: 187–196

    Google Scholar 

  9. Eilertsen E, Hart JW, Magnussen MP, Sorensen H, Arrigoni-Martelli E (1982) Pharmacokinetics and distribution of the new antihypertensive agent, pinacidil, in rat, dog and man. Xenobiotica 12 [3]: 177–185

    Google Scholar 

  10. Diem K (1962) Scientific tables. Documenta Geigy, New York, p 314

    Google Scholar 

  11. Riegelman S, Loo JCK, Rowland M (1968) Shortcomings in pharmacokinetic analysis by conceiving the body to exhibit properties of a single compartment. J Pharm Sci 57: 117–123

    Google Scholar 

  12. Shepherd AMM, McNay JL, Ludden TM, Lin MS, Musgrave GE (1981) Plasma concentration and acetylator status phenotype determine response to oral hydralazine. Hypertension 3: 580–585

    Google Scholar 

  13. Shepherd AMM, Musgrave GE, Badke FR, Walsh R (1980) Tachycardia associated with hydralazine pyruvic acid hydrazone, the major plasma metabolite of hydralazine. Fed Proc 39: p 1190 (abstract)

    Google Scholar 

  14. Bateman DN, Hobbs, DC, Twomey TM, Stevens EA, Rawlins MD (1979) Prazosin pharmacokinetics and concentration effect. Eur J Clin Pharmacol 16: 177–181

    Google Scholar 

  15. Elliott HL, McLean K, Sumner DJ, Meredith PA, Reid JL (1981) Immediate cardiovascular responses to oral prazosineffects of concurrent β-blockers. Clin Pharmacol Ther 29: 303–309

    Google Scholar 

  16. Elliott HL, Meredith PA, Sumner DJ, McLean K, Reid JL (1982) A pharmacodynamic and pharmacokinetic assessment of a new α-adrenoceptor antagonist, doxazosin (UK 33274) in normotensive subjects. Br J Clin Pharmacol 13: 699–703

    Google Scholar 

  17. Kardel T, Hilden T, Carlsen J, Trap-Jensen J (1981) N″-cyano-N-4-pyridyl-N′-1,2,2-trimethylpropylguanidine, a new vasodilating agent: acute effect on blood pressure and pharmacokinetics in hypertensive patients. J Cardiovasc Pharmacol 3: 1002–1007

    Google Scholar 

  18. Reece AP, Cozamanis I, Zacest R (1980) Kinetics of hydralazine and its main metabolites in slow and fast acetylators. Clin Pharmacol Ther 28: 769–778

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ward, J.W., McBurney, A., Farrow, P.R. et al. Pharmacokinetics and hypotensive effect in healthy volunteers of pinacidil, a new potent vasodilator. Eur J Clin Pharmacol 26, 603–608 (1984). https://doi.org/10.1007/BF00543493

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00543493

Key words

Navigation